Promoting Your 510(k)-Pending Device: 5 Questions About FDA's Policy
Executive Summary
A 510(k) submission rather than a 510(k) clearance is the threshold that a device firm needs to meet to begin advertising or displaying a product under a long-established, one-sentence agency policy. But important questions remain about proper application of this policy by industry, Hyman, Phelps & McNamara attorney Jeffrey Shapiro writes in this guest column.
You may also be interested in...
How Pharma Can Navigate Ups And Downs Of Vertical Integration In US
Together, we will improve patient health and experiences while lowering costs across the continuum of care.” This quote, from Andrew Witty, CEO of US health services management company Optum, after the company sealed its acquisition of DaVita Medical Group in 2019, encapsulates the oft-declared goals of vertical integration: efficiencies, improved quality of care, reduced costs. But is this the reality?
Quebec To List Enoxaparin Biosimilar As Valeo Pharma Prepares Launch
Canada’s Valeo Pharma says it intends to pursue discussions for the inclusion of its Redesca enoxaparin biosimilar on all other provincial formularies, after being backed for listing on the Quebec public health plan.
French Back Routine Six-Week Interval In COVID-19 Vaccine Dosing
France's health technology assessment body says that delaying by six weeks the second dose of the two mRNA vaccines approved for use against COVID-19 would allow at least 700,000 more people to receive their jab in the first month.
Need a specific report? 1000+ reports available
Buy Reports